Applications
Clinically validated VHH antibodies that can be readily assembled to create well differentiated next generation biotherapeutics.
Application of
LlamdA® Antibodies
LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics.
It can also be used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
Applications ofLlamdA® Antibodies |
Benefits ofLlamdA® Antibodies |
Direct Therapeutics |
VHH’s small size makes them advantageous for isolating binders to intractable targets (eg membrane proteins) and buried epitopes. Half life tunable via serum albumin binding VHH. |
VHH Bispecifics |
VHH can be combined with IgG to create bispecifics with novel mechanisms of action and high specificity. VHH-only multispecifics offer gain of selectivity and improved tumour penetration for solid tumours |
Antibody Drug Conjugates (ADC) |
VHH formattable to deliver payloads (Radio- nucleotides, toxins, RNAi) with high specificity and tunable on/off rates. |
VHH as targeting agent in Cell and Gene therapies |
Small, stable alternative to scFv. VHH offer improved developability and manufacturability. Novel VHH can be readily formatted for incorporation into cell and gene therapies. |
CAR-T |
VHH Features
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
